Charles River Laboratories and Valo Health have launched Logica, an AI-powered drug discovery solution that translates clients’ biological insights into optimized preclinical assets. Logica utilizes Valo’s AI-driven opal computational platform and Charles River’s preclinical development expertise. It features advanced predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, and in silico high-throughput screening. This integrated offering streamlines the translation of targets into drug candidates, leveraging Charles River’s extensive capabilities in high-throughput screening, medicinal chemistry, ADME, biology, pharmacology, and safety testing.

Logica offers two specialized programs: Advanceable Lead (Logica-AL) and Candidate (Logica-C). Logica-AL provides advanceable series with in-vitro ADME and selectivity profiles, while Logica-C rapidly advances these leads to deliver development candidates ready for IND studies. This AI-powered solution is designed to produce advanceable lead series 90% of the time and development candidates 58% of the time, driving innovation in drug discovery and expediting the delivery of effective treatments to patients.